{"id":3251,"date":"2024-04-16T18:19:58","date_gmt":"2024-04-16T15:19:58","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=3251"},"modified":"2024-04-16T18:20:11","modified_gmt":"2024-04-16T15:20:11","slug":"esgyi-gunluk-isimizin-onemli-bir-parcasi-olarak-goruyoruz-copy-copy","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=3251","title":{"rendered":"MSD, ESG Uygulamalar\u0131yla Payda\u015flar\u0131 ve Toplum i\u00e7in De\u011fer Yarat\u0131yor"},"content":{"rendered":"\n

MSD T\u00fcrkiye Hasta Eri\u015fim ve Kurumsal \u0130li\u015fkiler Direkt\u00f6r\u00fc U\u011fur Akpamuk, MSD\u2019nin s\u00fcrd\u00fcr\u00fclebilirlik stratejisini, etki alanlar\u0131n\u0131 ve kurum i\u00e7i giri\u015fimlerinin hayata ge\u00e7irdi\u011fi uygulamalar\u0131 anlatt\u0131.<\/strong><\/p>\n\n\n\n

MSD\u2019nin s\u00fcrd\u00fcr\u00fclebilirlik hedeflerine ula\u015fmas\u0131na y\u00f6nelik k\u00fcresel ESG stratejisinden bahseder misiniz?<\/strong><\/p>\n\n\n\n

MSD, 130 y\u0131l\u0131 a\u015fk\u0131n s\u00fcredir en zorlu hastal\u0131klarla m\u00fccadelede, hayatlar\u0131 kurtarma ve iyile\u015ftirme misyonuyla \u00e7al\u0131\u015f\u0131yor, \u00e7evresel, sosyal ve kurumsal y\u00f6neti\u015fim uygulamalar\u0131na (ESG) \u00f6nem vermenin toplum ve payda\u015flar i\u00e7in de\u011fer yaratt\u0131\u011f\u0131na inan\u0131yor. ESG\u2019yi yaln\u0131zca bir metrik olarak de\u011fil, g\u00fcnl\u00fck i\u015fin ve s\u00fcrd\u00fcr\u00fclebilir bir i\u015f olu\u015fturman\u0131n \u00f6nemli bir par\u00e7as\u0131 olarak g\u00f6r\u00fcyoruz. Vizyonumuz do\u011frultusunda hayat de\u011fi\u015ftiren \u00fcr\u00fcnler sunmak i\u00e7in \u00fcretimde verim kazand\u0131ran yat\u0131r\u0131mlar yap\u0131yor, kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lara y\u00f6nelik \u00e7\u00f6z\u00fcmlere eri\u015fimi geni\u015fletiyor, dijital teknolojiler ile \u00fcretkenli\u011fi art\u0131r\u0131yor ve \u00e7al\u0131\u015fanlar\u0131n geli\u015fimine yat\u0131r\u0131m yap\u0131yoruz. Bu sayede \u2018Stratejik Etki \u00c7er\u00e7evemiz\u2019 kapsam\u0131nda Sa\u011fl\u0131\u011fa Eri\u015fim, \u00c7al\u0131\u015fanlar\u0131m\u0131z, \u00c7evresel S\u00fcrd\u00fcr\u00fclebilirlik ve Etik & De\u011ferler\u2019den olu\u015fan d\u00f6rt alana dokunuyoruz.<\/p>\n\n\n\n

MSD, s\u00fcrd\u00fcr\u00fclebilirlik stratejisi do\u011frultusunda sa\u011fl\u0131\u011fa eri\u015fim alan\u0131nda ne gibi \u00e7al\u0131\u015fmalar yap\u0131yor?<\/strong><\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

MSD olarak her y\u0131l haz\u0131rlad\u0131\u011f\u0131m\u0131z Global Etki raporumuzda belirtildi\u011fi \u00fczere S\u00fcrd\u00fcr\u00fclebilirlik stratejimizle d\u00f6rt alana etki ediyor, bu alanlarda kapsaml\u0131 \u00e7al\u0131\u015fmalar ger\u00e7ekle\u015ftiriyoruz. Bir ila\u00e7 \u015firketi olarak, Sa\u011fl\u0131\u011fa Eri\u015fim odakland\u0131\u011f\u0131m\u0131z etki alanlar\u0131m\u0131z\u0131n ba\u015f\u0131nda geliyor.<\/p>\n\n\n\n

Sa\u011fl\u0131\u011fa Eri\u015fim alan\u0131ndaki yat\u0131r\u0131mlar\u0131m\u0131z ile k\u00fcresel bula\u015f\u0131c\u0131 hastal\u0131klar\u0131n \u00f6nlenmesindeki rol\u00fcm\u00fcz\u00fc g\u00fc\u00e7lendirmeyi hedeflerken, pek \u00e7ok tedavi alan\u0131nda kar\u015f\u0131lanmam\u0131\u015f ihtiya\u00e7lara \u00e7\u00f6z\u00fcm bulmak ve k\u00fcresel halk sa\u011fl\u0131\u011f\u0131n\u0131 korumak i\u00e7in \u00e7al\u0131\u015f\u0131yoruz. T\u00fcrk toplumunun yenilik\u00e7i tedavilere ve a\u015f\u0131lara erken eri\u015fim sa\u011flamas\u0131 hedefimiz do\u011frultusunda MSD T\u00fcrkiye Klinik Ara\u015ft\u0131rmalar Departman\u0131\u2019nda \u00e7al\u0131\u015fan deneyimli ve yetkin 180\u2019i a\u015fk\u0131n \u00e7al\u0131\u015fma arkada\u015f\u0131m\u0131zla birlikte \u2018Ya\u015fam \u0130\u00e7in Ke\u015ffediyoruz<\/em>\u2019. Klinik ara\u015ft\u0131rmalar alan\u0131nda MSD T\u00fcrkiye olarak son 5 y\u0131lda her sene ortalama y\u00fczde 15\u2019in \u00fczerinde art\u0131\u015fla T\u00fcrkiye\u2019deki ara\u015ft\u0131rma ve geli\u015ftirme yat\u0131r\u0131mlar\u0131m\u0131z\u0131 s\u00fcrd\u00fcr\u00fcyoruz. Bu s\u00fcre\u00e7te klinik \u00e7al\u0131\u015fma say\u0131s\u0131 y\u00fczde 16, \u00e7al\u0131\u015fmalara dahil edilen ve yenilik\u00e7i tedavilere erken eri\u015fim imkan\u0131na sahip olan g\u00f6n\u00fcll\u00fc say\u0131s\u0131 ise y\u00fczde 21 oran\u0131nda y\u0131ll\u0131k art\u0131\u015f sa\u011flad\u0131. H\u00e2lihaz\u0131rda 80\u2019den fazla hastanede 125\u2019ten fazla aktif klinik \u00e7al\u0131\u015fma y\u00fcr\u00fct\u00fcl\u00fcrken, 3 binden fazla g\u00f6n\u00fcll\u00fc yenilik\u00e7i tedavilere erken eri\u015fim imk\u00e2n\u0131na sahip oluyor.<\/p>\n\n\n\n

MSD\u2019nin herkes i\u00e7in sa\u011fl\u0131k e\u015fitli\u011fi yaratmaya odaklanan \u2018Sa\u011fl\u0131kta E\u015fitlik Kataliz\u00f6r Fonu (Health Equity Catalyst Fund)\u2019 ad\u0131nda k\u00fcresel bir giri\u015fimi bulunuyor. MSD T\u00fcrkiye olarak, \u00e7e\u015fitli dernek ve sivil toplum kurulu\u015flar\u0131 taraf\u0131ndan y\u00fcr\u00fct\u00fclen, hastalar\u0131n tedavilerine eri\u015fimlerini kolayla\u015ft\u0131ran projeleri destekliyoruz. Bunun yan\u0131 s\u0131ra, d\u00fcnyada anne sa\u011fl\u0131\u011f\u0131n\u0131 iyile\u015ftiren projelerin desteklemesine olanak tan\u0131yan \u2018Anneler i\u00e7in MSD (MSD for Mothers)\u2019 ad\u0131 verilen global bir kurumsal ba\u011f\u0131\u015f program\u0131 y\u00f6netiyoruz. Bu kapsamda hi\u00e7bir kad\u0131n\u0131n d\u00fcnyaya \u00e7ocuk getirirken \u00f6lmek zorunda olmad\u0131\u011f\u0131 bir d\u00fcnya yaratmaya yard\u0131mc\u0131 olmak i\u00e7in k\u00fcresel \u00e7apta 650 milyon dolarl\u0131k taahh\u00fcd\u00fcm\u00fcz bulunuyor. MSD T\u00fcrkiye olarak, 6 \u015eubat depreminin ard\u0131ndan ba\u015flatt\u0131\u011f\u0131m\u0131z fark\u0131ndal\u0131k projesiyle deprem b\u00f6lgesindeki kad\u0131n ve k\u0131z \u00e7ocuklar\u0131n\u0131n yarar\u0131na hayata ge\u00e7irilecek bir STK projesi i\u00e7in bu global fonu \u00fclkemize getirmeye hak kazand\u0131k.<\/p>\n\n\n\n

MSD\u2019nin s\u00fcrd\u00fcr\u00fclebilirlik stratejisi do\u011frultusunda oda\u011f\u0131ndaki di\u011fer \u00e7al\u0131\u015fmalar\u0131 neler?<\/strong><\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

\u00c7al\u0131\u015fanlar\u0131m\u0131z\u0131n en de\u011ferli varl\u0131klar\u0131m\u0131z oldu\u011fu fark\u0131ndal\u0131\u011f\u0131yla, onlar\u0131n yeteneklerini dengelemek ve u\u00e7tan uca geli\u015fmek i\u00e7in \u00e7e\u015fitlilik, e\u015fitlik ve dahil etme ilkelerimize ek olarak \u00e7evik \u00e7al\u0131\u015fma k\u00fclt\u00fcr\u00fcne de \u00e7ok \u00f6nem veriyoruz. \u00dcst d\u00fczey y\u00f6netim rollerindeki kad\u0131n temsiliyeti k\u00fcresel olarak her y\u0131l artarak devam ediyor. Liderlik Tak\u0131m\u0131\u2019n\u0131n y\u00fczde 75\u2019i kad\u0131n y\u00f6neticilerden olu\u015fan MSD T\u00fcrkiye olarak, kad\u0131n istihdam\u0131 ve e\u015fitli\u011fi do\u011frultusunda i\u015f d\u00fcnyas\u0131nda kad\u0131nlar\u0131n geli\u015fimine ve dahiliyetine katk\u0131 sa\u011flaman\u0131n \u00f6nemini biliyoruz. Women\u2019s Network platformumuzun bir par\u00e7as\u0131 olan \u2018Empowered\u2019 projesiyle kad\u0131n \u00f6\u011frencilerin i\u015f hayat\u0131na ge\u00e7i\u015fini kolayla\u015ft\u0131ran mentorluk deste\u011fi veriyoruz. Kat\u0131l\u0131mc\u0131 Liderlik giri\u015fimimizde projeler ve e\u011fitimlerle y\u00f6neticilerimizin ki\u015fisel yetkinliklerini geni\u015fletmelerine olanak sa\u011fl\u0131yor, mentorluk programlar\u0131yla ku\u015faklararas\u0131 i\u015f birli\u011fini art\u0131r\u0131yoruz. MSD Future Leaders program\u0131 ile kariyer hayat\u0131na yeni ad\u0131m atan yeteneklerimizi farkl\u0131 deneyimlerle g\u00fc\u00e7lendirerek gelece\u011fe y\u00f6nelik geli\u015fimlerini destekliyoruz.<\/p>\n\n\n\n

S\u00fcrd\u00fcr\u00fclebilirlik kapsam\u0131nda insan sa\u011fl\u0131\u011f\u0131n\u0131n temeli i\u00e7in sa\u011fl\u0131kl\u0131 bir gezegenin \u015fart oldu\u011funa inan\u0131yoruz. MSD T\u00fcrkiye\u2019de S\u00fcrd\u00fcr\u00fclebilirlik \u00c7evik Tak\u0131m\u0131 hem s\u00fcrd\u00fcr\u00fclebilirlik kavram\u0131n\u0131n benimsenmesi hem de \u00e7evresel s\u00fcrd\u00fcr\u00fclebilirlik ad\u0131na anlaml\u0131 ad\u0131mlar at\u0131lmas\u0131 amac\u0131yla olu\u015fturulmu\u015ftur. Bu tak\u0131m\u0131m\u0131z arac\u0131l\u0131\u011f\u0131yla \u015firket i\u00e7i e\u011fitimler d\u00fczenleyerek, s\u00fcrd\u00fcr\u00fclebilirlik oda\u011f\u0131nda bilgilendirici e-postalar payla\u015f\u0131yoruz. Ofis i\u00e7i plastik kullan\u0131m\u0131n\u0131 azaltma, at\u0131k pil toplama kutular\u0131n\u0131 yayg\u0131nla\u015ft\u0131rma, \u00e7al\u0131\u015fanlar\u0131 do\u011faya sayg\u0131l\u0131 \u00fcr\u00fcnlerle bulu\u015fturma gibi uygulamalarla \u00e7al\u0131\u015fma ortam\u0131m\u0131z\u0131n s\u00fcrd\u00fcr\u00fclebilirli\u011fine \u00f6zenle yakla\u015f\u0131yoruz. 6 ayda bir olmak \u00fczere \u00e7al\u0131\u015fanlar\u0131n fark\u0131ndal\u0131k seviyesini \u00f6l\u00e7me amac\u0131yla anket d\u00fczenleyerek \u00e7al\u0131\u015fmalar\u0131m\u0131z\u0131n verimlili\u011fini \u00f6l\u00e7\u00fcml\u00fcyoruz. Levent 199\u2019daki ofisimiz \u00e7evre dostu uygulamalar\u0131m\u0131z ile \u2018S\u0131f\u0131r At\u0131k Sertifikas\u0131\u2019n\u0131 almaya hak kazand\u0131 ve ABD Ye\u015fil Bina Konseyi de\u011ferlendirmesi sonucunda \u2018LEED Gold Sertifikas\u0131\u2019na l\u00e2y\u0131k g\u00f6r\u00fcld\u00fc.  <\/p>\n\n\n\n

Etik ve de\u011ferlerimizi yapt\u0131\u011f\u0131m\u0131z her \u015feyin temeline koyarak, \u015firketimizin karar verme s\u00fcrecini, uyum sa\u011flama yetene\u011fini ve g\u00fcvenilirli\u011fini geli\u015ftiren hesap verebilir bir k\u00fclt\u00fcr yarat\u0131yoruz. \u00c7al\u0131\u015fanlar\u0131n ve \u00fc\u00e7\u00fcnc\u00fc taraflar\u0131n endi\u015felerini anonim olarak da (yasalar\u0131n izin verdi\u011fi durumlarda) dile getirmelerine olanak tan\u0131yan \u015firket i\u00e7i raporlama kanallar\u0131n\u0131n 7\/24 eri\u015filebilirli\u011fi buna \u00f6rnek g\u00f6sterilebilir. Aktif olay izleme, risk\/zarar analizi ve veri ihlallerinin zaman\u0131nda bildirilmesine y\u00f6nelik yasal gerekliliklere tam uyum sa\u011flamay\u0131 hedefliyoruz.<\/p>\n\n\n\n

MSD Sosyal Akademi\u2019nin \u00e7\u0131k\u0131\u015f noktas\u0131 ve hedeflerinden bahseder misiniz?  <\/strong><\/p>\n\n\n\n

MSD Sosyal Akademi, MSD \u00e7al\u0131\u015fanlar\u0131n\u0131n i\u00e7indeki sosyal sorumluluk arzusunun ve dayan\u0131\u015fma ruhunun ortaya \u00e7\u0131kar\u0131ld\u0131\u011f\u0131 bir yap\u0131dan olu\u015fuyor. Sivil toplum kurulu\u015flar\u0131n\u0131 daha yak\u0131ndan tan\u0131yabilmek ad\u0131na \u201cToplumumuz ve \u00e7evremiz i\u00e7in sorumluyuz. Fikirlerimiz ve eylemlerimizle g\u00f6n\u00fcll\u00fcy\u00fcz\u201d mottosuyla Kurumsal \u0130leti\u015fim ekibimizin \u00f6nc\u00fcl\u00fc\u011f\u00fcnde MSD Sosyal Akademi\u2019yi hayata ge\u00e7irdik. MSD T\u00fcrkiye\u2019nin b\u00fct\u00fcn \u00e7al\u0131\u015fanlar\u0131n\u0131n do\u011fal bir \u00fcyesi oldu\u011fu akademide, T\u00fcrkiye’deki \u00e7evresel ve toplumsal fayday\u0131 art\u0131rmay\u0131 hedefleyen STK\u2019lar ile i\u015f birli\u011fi i\u00e7erisinde e\u011fitim ve sohbetler ger\u00e7ekle\u015ftirerek MSD’nin sosyal ve entelekt\u00fcel sermayesini toplumsal ihtiya\u00e7lar\u0131 kar\u015f\u0131lamak ad\u0131na harekete ge\u00e7irmeyi ama\u00e7l\u0131yoruz.<\/p>\n","protected":false},"excerpt":{"rendered":"

MSD T\u00fcrkiye Hasta Eri\u015fim ve Kurumsal \u0130li\u015fkiler Direkt\u00f6r\u00fc U\u011fur Akpamuk, MSD\u2019nin s\u00fcrd\u00fcr\u00fclebilirlik stratejisini, etki alanlar\u0131n\u0131 ve kurum i\u00e7i giri\u015fimlerinin hayata ge\u00e7irdi\u011fi uygulamalar\u0131 anlatt\u0131.<\/p>\n","protected":false},"author":1,"featured_media":3244,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,2],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3251"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3251"}],"version-history":[{"count":1,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3251\/revisions"}],"predecessor-version":[{"id":3252,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3251\/revisions\/3252"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/3244"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3251"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3251"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}